Of note, an inhibitory antibody against MASP-2 (Narsoplimab) is currently undergoing phase 3 clinical trials for the treatment of Hematopoietic Stem Cell Transplant-Associated TMA (ClinicalTrials.gov Identifier: NCT04247906), IgA Nephropathy (NCT03608033) and Atypical Hemolytic Uremic Syndrome (NCT03205995) and in a phase 2 clinical trial for the treatment of Lupus Nephritis (NCT02682407), thus making the present work potentially transferable to the clinical setting in the near future. Here, MASP2 is linked to IgA glomerulonephritis.